Innovent Reports the First Patients Dosing of Mazdutide (IBI362) in the P-III Study (DREAMS-2) for Type 2 Diabetes
Shots:
- The first patient has been dosed in a P-III trial (DREAMS-2) evaluating mazdutide (4.0/6.0mg) vs dulaglutide (1.5mg for 28wks.) in a ratio (1:1:1) in ~720 patients who have inadequate glycemic control with metformin monotx. or combination therapy of metformin with SGLT2 inhibitors or sulfonylureas
- The 1EPs will be the change from baseline to 28wk. in glycated hemoglobin (HbA1c) level. The P-II trial results were well tolerated & overall safety profile was similar to other GLP-1 class drugs with mean change in HbA1c & body weight from baseline to 20wk., lowering blood pressure, blood lipids & liver enzyme levels & other multiple benefits
- Innovent & Eli Lilly collaborated for OXM in China where Lilly is developing OXM3 outside of China
Ref: PRNewswire | Image: Innovent
Relatwed News:- Innovent Reports First Participant Dosing of Mazdutide (IBI362) in the P-III (GLORY-1) Trial for the Treatment of Overweight or Obesity
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
